arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BIOREGENX, INC.

BRGX
— Price unavailable
Technology ·Services-Computer Programming, Data Processing, Etc. ·USServices-Computer Programming, Data Processing, Etc.
19 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

BIOREGENX, INC. shows mixed fundamentals. However, watch Operating Margin (%) and Profit Margin (%) which show concerning trends. Consider comparing against peers in the Technology sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth -17.3% ↘
Op. Margin -11.7% ↗
ROIC 0.9% ↘
FCF / Share $0.00
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$426.18K
↓ -17.3% —
Net Income Profit after all expenses
$-26.41K
↑ +90.1% —
Operating Margin Operating profit as % of sales
-11.7%
↑ +95.2% 4th
FCF / Share Free cash flow per share
$0.00
↓ -30.2% —
Long-Term Debt Long-term obligations
$1.19M
↑ +492.5% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
12
Returns ↓
94
Financial Health ↑
69
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 19 quarters